Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific SessionPRNewsWire • 04/04/22
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate DevelopmentZacks Investment Research • 03/29/22
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral SclerosisPRNewsWire • 03/28/22
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of MedicinePRNewsWire • 03/16/22
Ionis calls for applications for Janice Wiesman Young Investigator Grant ProgramPRNewsWire • 03/07/22
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 02/24/22
Ionis reports fourth quarter and full year 2021 financial results and recent business achievementsPRNewsWire • 02/24/22
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 02/17/22
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to IonisZacks Investment Research • 02/01/22
BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?Benzinga • 02/01/22
Pfizer and Ionis announce discontinuation of vupanorsen clinical development programPRNewsWire • 01/31/22